Table 2.
Demographics and baseline characteristics
| Baseline characteristics | Pediatric patients (N = 241) |
|---|---|
| Age, years | |
| Mean (s.d.) | 6.3 (4.9) |
| Median (range) | 5.0 (<1.0–17.0) |
| Age stratification, years, n (%) | |
| <2 | 61 (25.3) |
| 2 to <6 | 63 (26.1) |
| 6 to <12 | 72 (29.9) |
| 12 to <18 | 45 (18.7) |
| Gender, n (%) | |
| Male | 159 (66.0) |
| Female | 82 (34.0) |
| Stem cell source, n (%) | |
| BM | 116 (48.1) |
| PBSC | 92 (38.2) |
| Cord blood unit(s) | 33 (13.7) |
| Donor typea, n (%) | |
| Matched unrelated | 100 (41.5) |
| Haploidentical | 49 (20.3) |
| Mismatchedb | 43 (17.8) |
| Cord blood unit(s) | 35 (14.5) |
| Matched related | 33 (13.7) |
| T-cell depletionc, n (%) | |
| ATG | 95 (39.4) |
| Alemtuzumab (Campath) | 62 (25.7) |
| Ex vivo | 53 (22.0) |
| None | 31 (12.9) |
| Time from AdV infection to AdV ≥ 1000 copies/ml, days | |
| Mean (s.d.) | 15.2 (24.5) |
| Median (range) | 7 (0.0–146.0) |
| IQR | 0.0–17.0 |
| <28 days, n (%) | 201 (83.4) |
| ≥28 days, n (%) | 40 (16.6) |
| Time from allo-HCT to AdV ≥ 1000 copies/ml, days | |
| Mean (s.d.) | 40.4 (38.8) |
| Median (range) | 26.0 (0.0–174.0) |
| IQR | 13.0–56.0 |
| <28 days, n (%) | 130 (53.9) |
| ≥28 days, n (%) | 111 (46.1) |
| Disease for which allo-HCT was conducted, n (%) | |
| Malignant | 148 (61.4) |
| Nonmalignant immunodeficient | 72 (29.9) |
| Nonmalignant immunocompetent | 21 (8.7) |
| dsDNA viral coinfections, n (%) | |
| None | 138 (57.3) |
| ≥1 dsDNA viral infection in addition to AdV | 103 (42.7) |
| Comorbiditiesd, n (%) | |
| None | 147 (61.0) |
| ≥1 | 94 (39.0) |
| Lymphocyte count at time of AdV viremia ≥ 1000 copies/ml, n (%) | |
| ≥900 | 14 (5.8) |
| 300–899 | 35 (14.5) |
| <300 | 192 (79.7) |
| Maximum stage GvHD among skin, liver, GI at the time of AdV viremia ≥ 1000 copies/ml, n (%) | |
| 0 | 174 (72.2) |
| 1 | 22 (9.1) |
| 2 | 17 (7.1) |
| 3 | 16 (6.6) |
| 4 | 12 (5.0) |
ATG antithymocyte globulin, BM bone marrow, GI gastrointestinal, IQR interquartile range, PBSC peripheral blood stem cell, s.d. standard deviation
aCategories are not mutually exclusive
bMismatching was determined according to standard practice at each study site
cA hierarchy was applied such that patients who received ex vivo T-cell depletion and ATG and/or alemtuzumab were counted in the ex vivo category
dListed in Supplementary Table 1